YMAB - Yマブス・セラピュ―ティクス (Y-mAbs Therapeutics Inc.) Yマブス・セラピュ―ティクス

 YMABのチャート


 YMABの企業情報

symbol YMAB
会社名 Y-mAbs Therapeutics Inc (Yマブス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Y-mAbs Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing the therapeutic products for the treatment of cancer. Its product pipeline includes naxitamab and omburtamab. The Company’s lead antibody programs target GD2 and B7-H3. The Company develops naxitamab for the treatment of pediatric patients with relapsed or refractory (R/R) neuroblastoma (NB) and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system (CNS) leptomeningeal metastases (LM). The Company also creates humanized affinity matured bispecific antibodies. In addition the Company has two B7-H3 targeting product candidates omburtamab- diethylenetriamine pentaacetate (DTPA) and huB7-H3 which are in pre-clinical stage.   Yマブス・セラピュ―ティクスは米国のバイオ医薬品企業。米国内におけるがんの治療薬の新規開発と商品化に焦点をあて事業を行う。主に、再発性・難治性の高い小児がんである神経芽細胞腫や、線維形成性小円形細胞腫瘍および、びまん性橋グリオ―マの治療薬としてNaxitamabやOmburtamabの臨床試験を手掛ける。本社所在地はニューヨーク。   Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.
本社所在地 230 Park Avenue 33rd Floor New York NY 10169 USA
代表者氏名 Thomas Gad トーマス・ガード
代表者役職名 Chairman of the Board President Founder Head of Business Development and Strategy
電話番号 +1 212-847-9841
設立年月日 42095
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 29人
url www.ymabs.com
nasdaq_url https://www.nasdaq.com/symbol/ymab
adr_tso
EBITDA EBITDA(百万ドル) -30.84800
終値(lastsale) 24.015
時価総額(marketcap) 0
時価総額 時価総額(百万ドル) 701.48050
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 631.32850
当期純利益 当期純利益(百万ドル) -30.86800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Y-mAbs Therapeutics Inc revenues was not reported. Net loss increased from $6.1M to $17.8M. Higher net loss reflects Research and development - Balancing val increase from $4.5M to $13.8M (expense) General and administrative - Balancing v increase from $1.3M to $2.9M (expense) Stock-based Compensation in SGA increase of 66% to $367K (expense).

 YMABのテクニカル分析


 YMABのニュース

   Y-mAbs Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA  2023/04/05 13:04:04 Investing.com
https://www.investing.com/news/assorted/ymabs-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-gd2sada-432SI-3049582
   Crude Oil Rises 1.5%; Checkpoint Therapeutics Shares Slide  2023/03/31 18:30:47 Benzinga
U.S. stocks traded higher toward the end of trading, with the Dow Jones jumping more than 200 points on Friday. The Dow traded up 0.72% to 33,095.32 while the NASDAQ rose 1.09% to 12,144.31. The S&P 500, also rose, gaining, 0.79% to 4,082.66. Check This Out: Check Out 3 High-Yielding Dividend Stocks In Real Estate Sector From Wall Street''s Most Accurate Analysts Leading and Lagging Sectors Consumer discretionary shares jumped by 1.8% on Friday. Meanwhile, top gainers in the sector included ContextLogic Inc. (NASDAQ: WISH ), up 13%, and Groupon, Inc. (NASDAQ: GRPN ), up 25%. In trading on Friday, utilities fell by 0.2%. Top Headline The personal consumption expenditure price index in rose by 5% year-over-year in February, the lowest since September 2021. The US core PCE price index, the Federal Reserve’s preferred inflation gauge, increased by 4.6% annually in February. Equities Trading UP Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB ) shares shot up 56% to $5.14 after the company posted a profit for the fourth quarter.
   BCLI, SOUN and IPDN among mid-day movers  2023/03/31 16:58:15 Seeking Alpha
Gainers: Y-mAbs Therapeutics YMAB +61%.Burford Capital Limited BUR +42%.Pulse Biosciences PLSE +29%.Brainstorm Cell Therapeutics (BCLI) +29%.Bionomics Limited (BNOX)…
   Nasdaq Surges Over 100 Points; G Medical Innovations Shares Plunge  2023/03/31 16:02:12 Benzinga
U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping more than 100 points on Friday. The Dow traded up 0.69% to 33,086.43 while the NASDAQ rose 1.01% to 12,134.43. The S&P 500, also rose, gaining, 0.78% to 4,082.51. Check This Out: Check Out 3 High-Yielding Dividend Stocks In Real Estate Sector From Wall Street''s Most Accurate Analysts Leading and Lagging Sectors Consumer discretionary shares jumped by 1.7% on Friday. Meanwhile, top gainers in the sector included Mullen Automotive, Inc. (NASDAQ: MULN ), up 14%, and Groupon, Inc. (NASDAQ: GRPN ), up 20%. In trading on Friday, utilities rose by just 0.2%. Top Headline The personal consumption expenditure price index in rose by 5% year-over-year in February, the lowest since September 2021. The US core PCE price index, the Federal Reserve’s preferred inflation gauge, increased by 4.6% annually in February. Equities Trading UP Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB ) shares shot up 76% to $5.80 after the company posted a profit for the fourth quarter.
   Y-mAbs Therapeutics, Inc. (YMAB) Q4 2022 Earnings Call Transcript  2023/03/31 15:08:09 Seeking Alpha
Y-mAbs Therapeutics, Inc. (NASDAQ:NASDAQ:YMAB) Q4 2022 Earnings Conference Call March 31, 2023 9:00 AM ETCompany ParticipantsThomas Gad - Founder, Interim CEO & PresidentSue Smith - SVP…
   YMAB 2-WEEK DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Pending  2023/03/06 21:01:00 GlobeNewswire
SAN FRANCISCO, March 06, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now .
   Y-MABS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options  2023/03/04 12:00:00 Benzinga
NEW YORK , March 4, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB ) and reminds investors of the March 20, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in Y-mAbs stock or options between October 6, 2020 and October 28, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . You may also click here for additional information: www.faruqilaw.com/YMAB . There is no cost or obligation to you. Faruqi & Faruqi is a leading … Full story available on Benzinga.com
   Y-MABS THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB  2023/03/04 03:50:00 Kwhen Finance
   Y-mAbs Therapeutics: Omburtamab CRL Hits Hard, But All Is Not Over (NASDAQ:YMAB)  2023/03/02 05:59:11 Seeking Alpha
Y-mAbs Therapeutics will need to do a new trial for its neuroblastoma drug omburtamab to get approval. Read more to see my thoughts on YMAB stock.
   YMAB SHAREHOLDER ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed  2023/02/27 22:07:00 GlobeNewswire
SAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now .
   Stocks to Watch: Neptune Wellness Solutions, Y-mAbs Therapeutics, Frequency Electronics  2022/12/16 23:17:00 MarketWatch
By Kathryn Hardison Neptune Wellness Solutions Inc. on Friday reported a wider loss for its fiscal second quarter. The consumer-packaged goods company''s…
   Is Y-mAbs Therapeutics Inc. (YMAB) a opportunity to investors?  2022/12/13 14:40:00 US Post News
A share of Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) closed at $4.88 per share on Monday, up from $4.36 day before. While Y-mAbs Therapeutics Inc. has overperformed by 11.93%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, YMAB fell by -70.13%, with highs and lows ranging from $20.48 […]
   Do investors need to be concerned about Y-mAbs Therapeutics Inc. (YMAB)?  2022/12/06 16:00:00 US Post News
The share price of Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) rose to $4.41 per share on Monday from $4.24. While Y-mAbs Therapeutics Inc. has overperformed by 4.01%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, YMAB fell by -73.03%, with highs and lows ranging from $20.48 to $2.94, […]
   Y-mAbs neuroblastoma therapy rejected by FDA  2022/12/02 17:38:32 Seeking Alpha
Shares of Y-mAbs Therapeutics (YMAB) ended three days of back-to-back gains after the oncology-focused biotech announced that the FDA rejected its investigational therapy I-omburtamab…
   How should investors view Y-mAbs Therapeutics Inc. (YMAB)?  2022/11/29 15:00:00 US Post News
Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) marked $4.18 per share on Monday, down from a previous closing price of $4.19. While Y-mAbs Therapeutics Inc. has underperformed by -0.24%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, YMAB fell by -75.63%, with highs and lows ranging from $20.48 to […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 Yマブス・セラピュ―ティクス YMAB Y-mAbs Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)